{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:02:51Z","timestamp":1784534571897,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcf.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:13:37Z","timestamp":1784531617000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world experience with a generic formulation of elexacaftor\/tezacaftor\/ivacaftor in children with cystic fibrosis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-689X","authenticated-orcid":false,"given":"Mar\u00eda Macarena","family":"Oneglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0681-211X","authenticated-orcid":false,"given":"Hilda","family":"Giugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Agustinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Plubatsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3662-5067","authenticated-orcid":false,"given":"Claudio","family":"Casta\u00f1os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jcf.2026.07.004_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 study group. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10059","key":"10.1016\/j.jcf.2026.07.004_bib0002","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.004_bib0003","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/MOP.0b013e3280109b90","article-title":"Advances in cystic fibrosis therapies","volume":"18","author":"Rowe","year":"2006","journal-title":"Curr Opin Pediatr"},{"issue":"5","key":"10.1016\/j.jcf.2026.07.004_bib0004","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4067\/S0034-98872014000500009","article-title":"Din\u00e1mica y patolog\u00eda del barrido mucociliar como mecanismo defensivo del pulm\u00f3n y alternativas farmacol\u00f3gicas de tratamiento","volume":"142","author":"P\u00e9rez","year":"2014","journal-title":"Rev Med Chile"},{"issue":"1","key":"10.1016\/j.jcf.2026.07.004_bib0005","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.00196314","article-title":"Future trends in cystic fibrosis demography in 34 European countries","volume":"46","author":"Burgel","year":"2015","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.jcf.2026.07.004_bib0006","first-page":"192","article-title":"Elexacaftor-tezacaftor-ivacaftor: the first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy","volume":"25","author":"Ridley","year":"2020","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jcf.2026.07.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01783-2025","article-title":"Advances in cystic fibrosis: CFTR modulator triple combinations","volume":"67","author":"Burgel","year":"2026","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jcf.2026.07.004_bib0008","article-title":"A review of Trikafta: triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.jcf.2026.07.004_bib0009","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jcf.2025.10.007","article-title":"Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor","volume":"24","author":"Burgel","year":"2025","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2026.07.004_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1399-0004.2002.610307.x","article-title":"Complete screening of the CFTR gene in Argentine cystic fibrosis patients","volume":"61","author":"Visich","year":"2002","journal-title":"Clin Genet"},{"key":"10.1016\/j.jcf.2026.07.004_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.jcf.2026.07.004_bib0012","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jcf.2022.04.007","article-title":"Current prices versus minimum costs of production for CFTR modulators","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2026.07.004_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2026.07.004_bib0014","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2026.07.004_bib0015","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/idr17040080","article-title":"Effects of CFTR modulators on Pseudomonas aeruginosa infections in cystic fibrosis","volume":"17","author":"Pescaru","year":"2025","journal-title":"Infect Dis Rep"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326016565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:13:39Z","timestamp":1784531619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326016565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"alternative-id":["S1569199326016565"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.07.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with a generic formulation of elexacaftor\/tezacaftor\/ivacaftor in children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}